Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2-infected patients in West Africa

AIDS

Volumn 14, Issue 4, 2000, Pages 339-344

  Ariyoshi, Koya ^a   Jaffar, Shabbar ^b   Alabi, Abraham S ^d   Berry, Neil ^c   Van der Loeff, Maarten Schim ^d   Sabally, Sehu ^d   N'Gom, Pa Tamba ^d   Corrah, Tumani ^d   Tedder, Richard ^c   Whittle, Hilton ^d  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d NONE

Author keywords

CD4; HIV 2; Prognosis; Progression; Viral load

Indexed keywords

CD4 ANTIGEN; VIRUS DNA; VIRUS RNA;

ADULT; AFRICA; AGED; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; T LYMPHOCYTE; VIRUS LOAD;

EID: 0034069264     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200003100-00006     Document Type: Article

References (39)

1. 1. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994, 265:1587-1590.
2. 2. Whittle H, Morris J, Todd J, et al. HIV-2-infected patients survive longer than HIV-1-infected patients. AIDS 1994, 8:1617-1620.
3. 3. Jaffar S, Wilkins A, Ngom PT, et at. Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:327-332.
4. 4. Ricard D, Wilkins A, N'Gum PT, et al. The effects of HIV-2 infection in a rural area of Guinea-Bissau. AIDS 1994, 8: 977-982.
5. 5. Poulsen AG, Aaby P, Larsen O, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet 1997, 349:911-914.
6. 6. Nunn AJ, Mulder DW, Kamali A, Ruberantwari A, Kengeya-Kayondo JF, Whitworth J. Mortality associated with HIV-1 infection over five years in a rural Ugandan population: cohort study. Br Med J 1997, 315:767-771.
7. 7. Clavel F, Mansinho K, Chamaret S, et al. Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med 1987, 316:1180-1185.
8. 8. van der Ende ME, Schutten M, Ly TD, Gruters RA, Osterhaus AD. HIV-2 infection in 12 European residents: virus characteristics and disease progression. AIDS 1996, 10:1649-1655.
9. 9. Whittle HC, Ariyoshi K, Rowland-Jones S. HIV-2 and T cell recognition. Curr Opin Immunol 1998, 10:382-387.
10. 10. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
11. 11. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
12. 12. Mellors JW, Rinaldo CRJ, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
13. 13. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
14. 14. de Wolf F, Spijkerman I, Schellekens PT, et al. AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997, 11:1799-1806.
15. 15. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
16. 16. Simon F, Matheron S, Tamalet C, et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993, 7: 1411-1417.
17. 17. Berry N, Ariyoshi K, Jobe O, et al. HIV type 2 proviral load measured by quantitative polymerase chain reaction correlates with CD4+ lymphopenia in HIV type 2-infected individuals. AIDS Res Hum Retroviruses 1994, 10:1031-1037.
18. 18. Ariyoshi K, Berry N, Wilkins A, et al. A community-based study of human immunodeficiency virus type 2 provirus load in rural village in West Africa. J Infect Dis 1996, 173:245-248.
19. 19. Berry N, Ariyoshi K, Jaffar S, et al. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol 1998, 1:457-468.
20. 20. O'Donovan D, Ariyoshi K, Milligan P, et al. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. AIDS 2000, 4:441-448.
21. 21. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995, 332: 201-208.
22. 22. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209-216.
23. 23. Rey-Cuille MA, Berthier JL, Bomsel-Demontoy MC, et al. Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J Virol 1998, 72:3872-3886.
24. 24. Albert J, Naucler A, Bottiger B, et al. Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. AIDS 1990, 4:291-295.
25. 25. Grassly NC, Xiang Z, Ariyoshi K, et al. Mortality among human immunodeficiency virus type 2-positive villagers in rural Guinea-Bissau is correlated with viral genotype. J Virol 1998, 72:7895-7899.
26. 26. Gotch F, McAdam SN, Allsopp CE, et al. Cytotoxic T cells in HIV2 seropositive Gambians. Identification of a virus-specific MHC-restricted peptide epitope. J Immunol 1993, 151: 3361-3369.
27. 27. Ariyoshi K, Cham F, Berry N, et al. HIV-2-specific cytotoxic T-lymphocyte activity is inversely related to proviral load. AIDS 1995, 9:555-559.
28. 28. Bjorling E, Scarlatti G, von Gegerfelt A, et al. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 1993, 193:528-530.
29. 29. Tamalet C, Simon F, Dhiver C, et al. Autologous neutralizing antibodies and viral load in HIV-2-infected individuals. AIDS 1995, 9:90-91.
30. 30. McKnight A, Dittmar MT, Moniz-Periera J, et al. A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4. J Virol 1998, 72:4065-4071.
31. 31. Morner A, Bjorndal A, Albert J, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999, 73:2343-2349.
32. 32. Guillon C, van der Ende ME, Boers PH, Gruters RA, Schutten M, Osterhaus AD. Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their sycytium-inducing capacities. J Virol 1998, 72:6260-6263.
33. 33. Owen SM, Ellenberger D, Rayfield M, et al. Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J Virol 1998, 72:5425-5432.
34. 34. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862.
35. 35. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997, 277: 959-965.
36. 36. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998, 279:389-393.
37. 37. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998, 282:1907-1911.
38. 38. Liu H, Chao D, Nakayama EE, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA 1999, 96:4581-4585.
39. 39. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999, 283:1748-1752.